产品
编 号：F471705
分子式：C21H25N5O8S2
分子量：539.58
分子式：C21H25N5O8S2
分子量：539.58
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
160
In-stock
10mg
259
In-stock
25mg
492
In-stock
50mg
788
In-stock
100mg
1260
In-stock
结构图
CAS No: 82956-11-4
产品详情
生物活性：
Nafamostat mesylate (FUT-175), an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat mesylate has anticancer and antivirus effect. Nafamostat mesylate induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1). Nafamostat mesylate can be used in the development of the pathological thickening of the arterial wall3].
体内研究：
Nafamostat mesylate (10 mg/kg，腹腔注射，一天一次，持续 18 天) 对寨卡病毒 (ZIKV) 感染的 A129 小鼠具有良好的抗病毒作用。Nafamostat mesylate (0.5-2.0 mg/mL (溶于生理盐水中)，腹腔注射，一天一次，连续 7 天) 对大鼠颈动脉壁球囊损伤后新生内膜形成有抑制作用。Animal Model:A129 mice
Dosage:10 mg/kg
Administration:Intraperitoneal injection (i.p.)
Result:Exhibit delayed lethality and improved survival (40%).
Animal Model:Balloon injury of the rat carotid wall
Dosage:0.5 mg/mL, 1 mg/mL, 2 mg/mL (dissolved in saline)
Administration:Intraperitoneal injection (i.p.)
Result:Showed smaller ratios of the neointima/medial area.Showed positive but reduced immunoreactivity of the cells in the neointimal.
体外研究：
Nafamostat mesylate (10-80 μg/mL, 3-48 h) 通过阻断 IκBα 磷酸化抑制 MDAPanc-28 细胞 NF-κB 活性。Nafamostat mesylate (80 μg/mL, 24-48 h) 通过上调肿瘤坏死因子受体 1 (TNFR1) 的表达诱导 MDAPanc-28 细胞凋亡。Nafamostat mesylate (0.1-10 μM, 24 h) 对 Panc-1 细胞的侵袭能力有抑制作用。
Nafamostat mesylate (FUT-175), an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat mesylate has anticancer and antivirus effect. Nafamostat mesylate induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1). Nafamostat mesylate can be used in the development of the pathological thickening of the arterial wall3].
体内研究：
Nafamostat mesylate (10 mg/kg，腹腔注射，一天一次，持续 18 天) 对寨卡病毒 (ZIKV) 感染的 A129 小鼠具有良好的抗病毒作用。Nafamostat mesylate (0.5-2.0 mg/mL (溶于生理盐水中)，腹腔注射，一天一次，连续 7 天) 对大鼠颈动脉壁球囊损伤后新生内膜形成有抑制作用。Animal Model:A129 mice
Dosage:10 mg/kg
Administration:Intraperitoneal injection (i.p.)
Result:Exhibit delayed lethality and improved survival (40%).
Animal Model:Balloon injury of the rat carotid wall
Dosage:0.5 mg/mL, 1 mg/mL, 2 mg/mL (dissolved in saline)
Administration:Intraperitoneal injection (i.p.)
Result:Showed smaller ratios of the neointima/medial area.Showed positive but reduced immunoreactivity of the cells in the neointimal.
体外研究：
Nafamostat mesylate (10-80 μg/mL, 3-48 h) 通过阻断 IκBα 磷酸化抑制 MDAPanc-28 细胞 NF-κB 活性。Nafamostat mesylate (80 μg/mL, 24-48 h) 通过上调肿瘤坏死因子受体 1 (TNFR1) 的表达诱导 MDAPanc-28 细胞凋亡。Nafamostat mesylate (0.1-10 μM, 24 h) 对 Panc-1 细胞的侵袭能力有抑制作用。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备